Coronavirus company news summary - Facedrive to supply rapid antigen tests in Canada - AMI Health collaborates with LifeSign to offer multiplexed test - Verdict Medical Devices
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – Facedrive to supply rapid antigen tests in Canada – AMI Health collaborates with LifeSign to offer multiplexed test

04 Aug 2021

Facedrive has commenced a supply, training and collection programme for the Government of Canada’s Covid-19 rapid antigen tests for small and medium-sized organizations. The tests will be distributed in the province of Ontario in a bid to mitigate the spread of the SARS-CoV-2 virus. The company will supply via its partner network, provide pick-up options and equipment for safe disposal of used tests and gather usage information.

BioVaxys Technology has reported that its CoviDTH disposable point-of-care diagnostic tool was demonstrated to be safe and effective for screening T cell-mediated immune response to SARS-CoV-2. CoviDTH is could  be used to help doctors to understand immunogenicity and T-cell immune responses for detection in exposed and vaccinated people.

US-based AMI Health has collaborated with LifeSign to provide a multiplexed Covid-19/Flu A&B test for the coming respiratory season. Available via AMI Expeditionary Healthcare, the LifeSign Status test can be used by testing centres, labs, hospitals, medical offices and clinics globally. The qualitative assay can identify SARS-CoV-2 antigen and influenza A&B antigen simultaneously using nasopharyngeal swabs and delivers results within 15 minutes.